VCYT — Veracyte Inc
NASDAQ · Healthcare · Diagnostics & Research
$44.50
+$1.07 (+2.46%)
Veracyte Inc (VCYT) is a diagnostics & research company listed on NASDAQ. It is led by Marc A. Stapley, based in 6000 Shoreline Court, South San Francisco, CA, United States, 94080, with about 755 employees. Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Latest reported VCYT revenue for 2025-09-30 was $131.9M. Net income was $19.1M. Revenue was up 1.3% from 2025-06-30 to 2025-09-30. VCYT currently screens at market cap $4.09B and trailing P/E 47.5.
Use this VCYT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VCYT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VCYT SEC filings page. Lician reads the product cache first so this HTML stays unique to Veracyte Inc even when a live quote feed is slow.
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Key Statistics
Market Cap
$4.09B
Volume
1.49M
Previous Close
$44.04
Day Range
$43.25 – $44.52
P/E Ratio
47.49
P/B Ratio
3.02
EPS
$0.31
Revenue
$445.76M
Net Income
$24.14M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+23.5%
Profit Margin
5.4%
Employees
755
VCYT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $445.76M | $361.05M | $296.54M | $219.51M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $24.14M | -$74.40M | -$36.56M | -$75.56M |
| EPS (Diluted) | $0.31 | -$1.02 | -$0.51 | -$1.11 |
Total Assets
$1.30B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$239.09M
Operating Cash Flow
$75.10M
Free Cash Flow
$0.00
Veracyte Inc Company Information
- CEO & Director
- Marc A. Stapley
- Headquarters
- 6000 Shoreline Court, South San Francisco, CA, United States, 94080
- Website
- www.veracyte.com
- Phone
- 650 243 6300
- IPO / Founded
- 2013-10-30
- Sector
- Healthcare
- Industry
- Diagnostics & Research